Cargando…
Development of a Chimeric Vaccine Against Pseudomonas aeruginosa Based on the Th17-Stimulating Epitopes of PcrV and AmpC
Pulmonary infection caused by Pseudomonas aeruginosa (PA) has created an urgent need for an efficient vaccine, but the protection induced by current candidates is limited, partially because of the high variability of the PA genome. Antigens targeting pulmonary Th17 responses are able to provide anti...
Autores principales: | Wang, Ying, Cheng, Xin, Wan, Chuang, Wei, Jinning, Gao, Chen, Zhang, Yi, Zeng, Hao, Peng, Liusheng, Luo, Ping, Lu, Dongshui, Zou, Quanming, Gu, Jiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859429/ https://www.ncbi.nlm.nih.gov/pubmed/33552056 http://dx.doi.org/10.3389/fimmu.2020.601601 |
Ejemplares similares
-
Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa
por: Wan, Chuang, et al.
Publicado: (2019) -
Self-assembled ferritin nanoparticles displaying PcrV and OprI as an adjuvant-free Pseudomonas aeruginosa vaccine
por: Li, Yuhang, et al.
Publicado: (2023) -
Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models
por: Yang, Feng, et al.
Publicado: (2017) -
In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways
por: Skoglund, Erik, et al.
Publicado: (2018) -
Corrigendum to “In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways”
por: Skoglund, Erik, et al.
Publicado: (2019)